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Abstract
Background: Nephrolithiasis is a global healthcare problem with a current lifetime risk of 18.8% in men and 9.4% in
women. Given the high cost of medical treatments and surgical interventions as well as the morbidity related to
symptomatic stone disease, medical prophylaxis for stone recurrence is an attractive approach. Thiazide diuretics have
been the cornerstone of pharmacologic metaphylaxis for more than 40 years. However, evidence for benefits and
harms of thiazides in the prevention of calcium containing kidney stones in general remains unclear. In addition, the
efficacy of the currently employed low dose thiazide regimens to prevent stone recurrence is not known.
Methods: The NOSTONE trial is an investigator-initiated 3-year prospective, multicenter, double-blind, placebo-controlled
trial to assess the efficacy of standard and low dose hydrochlorothiazide treatment in the recurrence prevention of
calcium containing kidney stones. We plan to include 416 adult (≥ 18 years) patients with recurrent (≥ 2 stone episodes
in the last 10 years) calcium containing kidney stones (containing ≥50% of calcium oxalate, calcium phosphate or a
mixture of both). Patients will be randomly allocated to 50mg or 25mg or 12.5mg hydrochlorothiazide or placebo.
The primary outcome will be incidence of stone recurrence (a composite of symptomatic or radiologic recurrence).
Secondary outcomes will be individual components of the composite primary outcome, safety and tolerability of
hydrochlorothiazide treatment, changes in urinary biochemistry elicited by hydrochlorothiazide treatment and impact of
baseline disease severity, biochemical abnormalities and stone composition on treatment response.
Discussion: The NOSTONE study will provide long-sought information on the efficacy of hydrochlorothiazide in the
recurrence prevention of calcium containing kidney stones. Strengths of the study include the randomized, double-blind
and placebo-controlled design, the large amount of patients studied, the employment of high sensitivity and high
specificity imaging and the exclusive public funding support.
Trial registration: ClinicalTrials.gov, NCT03057431. Registered on February 20 2017.
Keywords: Nephrolithiasis, Kidney stones, Recurrence, Prevention, Hydrochlorothiazide
* Correspondence: daniel.fuster@insel.ch
1Department of Nephrology and Hypertension, Inselspital, Bern University
Hospital, University of Bern, Bern, Switzerland
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Dhayat et al. BMC Nephrology          (2018) 19:349 
https://doi.org/10.1186/s12882-018-1144-6
Background
Nephrolithiasis is a worldwide healthcare problem with a
current lifetime risk of ~ 18.8% in men and ~ 9.4% in
women in Western civilizations [1]. Incidence and preva-
lence of renal stone disease are increasing globally, irrespect-
ive of age, sex and race [1, 2]. Without a specific treatment,
5- and 20-year recurrence rates are ~ 40% and ~ 75%,
respectively [3, 4]. In the United States, hospitalizations,
surgery and lost work time associated with kidney stones
cost more than 5 billion US Dollars annually [5]. Thus, given
the high cost and the morbidity related to recurrent kidney
stone disease, medical prophylaxis seems to be an attractive
approach [6, 7]. Indeed, apart from its benefits to patients in
terms of reduced morbidity and risk from procedures, med-
ical prevention of nephrolithiasis is clearly cost effective [8].
Eighty to 90% of stones are composed of calcium oxalate,
calcium phosphate or a mixture of both [9, 10]. Increased
excretion of calcium in the urine, hypercalciuria, is the
most frequent metabolic abnormality encountered in
patients with recurrent nephrolithiasis [10, 11]. The hyper-
calciuria encountered in recurrent stone formers is often
familial and strongly influenced by diet, but in most cases
of unknown origin and hence designated “idiopathic” [3].
Gut absorption of calcium is enhanced in idiopathic hyper-
calciuria, but serum calcium remains typically normal
because intestinally absorbed calcium is promptly excreted
by the kidneys [12]. Despite intestinal calcium hyperabsorp-
tion, patients with idiopathic hypercalciuria are often in
negative calcium balance because of excessive renal calcium
losses, especially under a low calcium diet [13, 14]. As a
consequence, low bone mass is a frequent finding in
normo- and especially hypercalciuric stone formers [15].
Thiazide diuretics are the only drugs known to reduce urin-
ary calcium excretion. This peculiar property is employed
in the prevention of recurrent calcium nephrolithiasis but
also in the prevention of bone loss in patients with recur-
rent nephrolithiasis and/or arterial hypertension [15–20].
The efficacy of thiazides in the recurrence prevention of
kidney stones has been studied in several randomized con-
trolled trials (RCTs) (Table 1) [21–31]. With the exception
of two trials [29, 31], thiazides significantly reduced stone
recurrence compared to placebo or control. However, as
detailed in Table 1 and highlighted by a recent systematic
review [32], thiazide RCTs thus far conducted suffer from
significant methodological deficiencies, including: use of
high thiazide doses, low overall number of patients studied,
lack of outcome uniformity, use of outdated dietary
recommendations, unclear allocation concealment, lack of
double-blinding and intention-to-treat analysis,
absence of adverse event and drop out reporting, un-
known baseline risk of disease severity and baseline
biochemical abnormalities of patients studied, lack of
patient stratification and employment of low sensitiv-
ity and specificity imaging modalities.
Hydrochlorothiazide (HCTZ) was used in five of the
11 thiazide RCTs for stone prevention and is thus cur-
rently the best studied thiazide in the prevention of
stone recurrence [23, 26, 28, 30, 31]. However, other
thiazides such as bendroflumethiazide, chlorthalidone,
trichlormethiazide and indapamide also reduced stone
recurrence in one or more trials and seem to be effective
as well. In all trials, high thiazide doses were employed,
in the case of HCTZ, 50–100mg daily. In four of the
five HCTZ trials, the diuretic was given twice daily,
whereas in the treatment of arterial hypertension, HCTZ
is typically given once daily [33]. Once daily HCTZ at
the dose of 50 mg, 25 mg or 12.5 mg reduces calciuria in
healthy volunteers, a surrogate marker for stone preven-
tion [34]. Detailed HCTZ dose-response studies with
respect to urinary composition and stone recurrence are
lacking. Twice daily HCTZ increases the frequency of
side effects and augments diuresis at night and thereby
likely affects compliance [33, 34].
A recent study revealed that thiazide diuretics are often
not used in an evidence-based fashion for the prevention
of stone recurrence [35]. The tendency to prescribe lower
doses of thiazides in patients with recurrent nephrolithia-
sis was likely triggered by a paradigm shift in prescribing
practices for thiazides used for the treatment of arterial
hypertension. Starting in the 1980’s, lower doses of HCTZ
(12.5–25mg daily) were increasingly employed [36].
While clinical and biochemical side effects were noted to
be dose-dependent, the antihypertensive effects remained
robust, even at lower doses [36, 37]. In the case of recur-
rent nephrolithiasis, however, this practice is not
supported by randomized evidence and consequently, we
do not know whether the currently employed low dose
thiazide regimens are effective in reducing the risk for
stone recurrence.
Thus, evidence for benefits and harms of thiazides in
the prevention of calcium containing kidney stones in
general remains unclear. In addition, the efficacy of the
currently employed low dose thiazide regimens to
prevent stone recurrence is not known.
Methods / design
Study objectives
Overall objective
The NOSTONE study aims to describe an efficacy and
safety profile of HCTZ for the recurrence prevention of
calcium nephrolithiasis.
Primary objective
Dose-response relationship for three different dosages
of HCTZ using incidence of stone recurrence (a com-
posite of symptomatic or radiologic recurrence) as the
primary outcome.
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Secondary objectives
Efficacy of the different dosages of HCTZ in terms of the
primary outcome as well as the individual components of
the composite primary outcome, i.e. incidence of symp-
tomatic stone recurrence and incidence of radiologic
stone recurrence. Effects of different dosages of HCTZ on
urinary biochemistry (efficacy and safety aspects) and the
impact of different baseline characteristics on the effects
of the different dosages (effect modification).
Safety objectives
Long-term safety and tolerability of HCTZ compared to
placebo.
Study outcomes
Primary outcome
The primary outcome of the NOSTONE study is the inci-
dence of stone recurrences during study treatment. Stone
recurrence is the composite of symptomatic or radiological
recurrences. Symptomatic stone recurrence is defined as vis-
ible passage of a stone or typical symptoms such as colicky
flank/loin pain with hematuria or any stone (symptomatic
or asymptomatic) requiring urological intervention for stone
removal. Radiological stone recurrence as assessed by
low-dose non-intravenous contrast CT imaging is defined as
the appearance of new calculi or enlargement of preexisting
calculi with reference to the baseline CT performed at
randomization.
Secondary outcomes
(i) The individual components of the composite pri-
mary outcome, i.e. number of symptomatic stone recur-
rences and number of radiologic stone recurrences.
(ii) Changes in urinary biochemistry elicited by HCTZ
or placebo.
(iii) Impact of baseline disease severity (incidence of
stone recurrence during the last 10 years prior to
randomization) and biochemical abnormalities on stone
recurrence.
(iv) Impact of stone composition on stone recurrence.
Safety outcomes
Safety endpoints to be analyzed include a descriptive
summary of the following parameters:
i) SAEs.
ii) Pre-specified AEs of special interest including:
– Hypokalemia, defined as blood potassium level <
3 mmol/L.
– Hyponatremia, defined as blood sodium level <
125 mmol/L.
– Hypomagnesemia, defined as blood magnesium
level < 0.5 mmol/L.
– Gouty arthritis if recurrence > 3 times per year
or requiring uric acid lowering therapy.
– Newly developed overt diabetes mellitus (defined
as fasting glucose level ≥ 7 mmol/L or random
Glucose ≥11 mmol/L or hemoglobin A1c ≥ 6.5%).
– Allergic reaction of skin if considered by the
local investigator to be potentially related to the
study medication.
iii) Vital signs.
– Heart rate, systolic and diastolic blood pressure
at the right arm in sitting position after at least
5 min rest will be recorded at all study visits.
Study design
The NOSTONE study is an investigator-initiated, ran-
domized, multicenter, double-blind, placebo-controlled
phase III trial in which 416 participants will be random-
ized to four parallel groups (104 participants per group)
to receive HCTZ 12.5 / 25 mg / 50 mg or placebo. All
subjects will be given the investigational medicinal prod-
uct (IMP - HCTZ or placebo) once daily in the morning
(Fig. 1). Placebo will be administered to individuals ran-
domized to that treatment group in a form identical to
the HCTZ capsules. The first IMP dose will be adminis-
tered the day after the randomization.
Randomization lists are generated by a statistician at
CTU Bern, the Clinical Trials Unit of the University of
Bern, otherwise not involved in the trial, following dedi-
cated standard operating procedures. Moreover, partici-
pants are stratified at randomization according to the
number of stone episodes in the last 10 years. Partici-
pants with two or three stone episode are clustered in
the first stratification group, participants with four or
more stones are allocated to a second stratification
group. All participants will receive state-of-the-art
non-pharmacologic recommendations for stone preven-
tion according to current American [38] and European
[16] nephrolithiasis guidelines including: increased fluid
intake with circadian drinking to ensure daily urinary
volumes of at least 2–2.5 L, a balanced diet rich in vege-
tables and fibers with normal calcium content (1–1.2 g/
day) but limited sodium chloride (4–6 g/day) and animal
protein (0.8–1 g/kg/day) content. Furthermore, partici-
pants will be advised to retain a normal BMI, have ad-
equate physical activity and balance excessive fluid loss.
Participants are followed for a minimum of 24months
and a maximum of 36months.
Study sites
The study is performed at 12 Departments of Nephrol-
ogy sites throughout Switzerland including seven Can-
tonal Hospitals (Aarau, Bellinzona, Chur, Lugano,
Luzern, Sion, St. Gallen) and five University Hospitals
(Basel, Bern, Geneva, Lausanne, Zürich).
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Study population
Eligibility criteria
Participants will be recruited according to the eligibility
criteria detailed in Table 2.
Criteria for withdrawal / discontinuation of participants
Criteria of IMP discontinuation or study discontinuation
are listed in Table 3. Participants who permanently dis-
continue the IMP are expected to continue in the
follow-up period and to attend all protocol-specified
study visits. If study visits are not possible, a telephone con-
sultation will be performed to determine if relevant health
events / endpoints have occurred. A study participant who
discontinues study participation prematurely for any reason
is defined as dropout if the participant has already been
randomized. A study participant who terminates the study
before randomization is regarded as a screening failure.
Study assessments
Outpatients referred to stone clinics for metabolic stone
work-up will be recruited for the trial. For work-up and
follow-up visits of participants, the NOSTONE protocol
strictly adheres to recommendations of the American and
European guidelines on nephrolithiasis with regard to sched-
uling of patient visits, lab analyses and imaging [16, 38]. Prior
to randomization, patients will undergo a screening visit to
check health status (including lab values), eligibility and
determine stone history. At randomization, eligible patients
will undergo a low-dose, renal-limited non-iv contrast CT
and receive the assigned IMP. Participants enrolled in the
trial will be followed-up 3months after randomization and
thereafter with yearly visits and every 3months through
phone calls. Symptomatic recurrence will be assessed at
follow-up visits and during phone calls between visits.
Radiologic recurrence will be assessed at treatment end by a
low-dose, renal-limited non-iv contrast CT.
Investigational medicinal product (IMP)
HCTZ (ATC code: C03AA03) is one of the best studied
thiazides on the market. Thiazides inhibit the sodium/
chloride co-transporter (NCC or SLC12A3) in the distal
tubule of the kidney. Inhibition of NCC causes an in-
creased excretion of sodium, chloride and water in the
urine, thereby lowering blood pressure. At the same
time, thiazides reduce renal calcium excretion by a still
ill-defined intrarenal mechanism. In Switzerland, HCTZ
as monosubstance is marketed exclusively as Esidrex® by
Medius AG, CH-4132 Muttenz, Switzerland in divisible
tablets of 25 mg. The approved indications include: ar-
terial hypertension, edemas, heart failure and recurrence
Fig. 1 Flow diagram of the NOSTONE trial
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prevention of calcium-containing kidney stones. For the
treatment of arterial hypertension, Esidrex® is recom-
mended in doses of 12.5–50mg, once or twice daily. For
the recurrence prevention of calcareous nephrolithiasis,
Esidrex® is recommended in doses of 25 or 50 mg twice
daily. In addition to the monosubstance, HCTZ is cur-
rently available in 75 different galenic formulations in
Switzerland as combination with ACE-inhibitors, angio-
tensin II receptor blockers or non-thiazide diuretics
(www.swissmedicinfo.ch, last accessed on 01.09.2018).
The encapsulated IMP will be provided by Laboratorium
Dr. G. Bichsel AG, Interlaken, Switzerland.
Statistical methods
Sample size
Sample size calculation was based on the primary object-
ive i.e. to assess the dose-response relationship and the
primary outcome i.e. recurrence with the following as-
sumptions: (i) uniform recruitment over 24 months with
allocation ratio fixed at 1 across all arms; (ii) a maximum
and minimum follow-up time of 36 and 24months, re-
spectively; (iii) cumulative drop-out rate of 10% at 24
months after study start; (iv) risk of recurrence in the
Table 3 Criteria for withdrawal / discontinuation of participants
Discontinuation of study investigational medicinal product
Study IMP must be permanently discontinued if any of the following
occurs:
- If any exclusion criterion applies during the trial, except the
incompatible medications. The IMP will be discontinued only if the
patient took the medications listed in the exclusion criteria for more
than 4 months
- If the responsible study investigator feels that treatment with the
study regimen is harmful to the participant’s well-being
- If patient is non-compliant with the study intervention as judged by
the investigator and/or the sponsor
- Pregnancy in a study participant
- Hypokalemia (blood potassium level < 3 mmol/L) not responsive to
supplementation therapy
- Profound hyponatremia (blood sodium level < 125mmol/L)
recurring after temporary suspension of IMP
- CKD-EPI eGFR < 30mL/min per 1,73 m2 body surface area for more
than 3 months
- Gouty arthritis recurring > 3 times per year or requiring uric acid
lowering therapy
- Allergic reaction of skin as judged by the investigator
- > 3 recurrences of symptomatic stone events during the trial
Discontinuation of study
Study participants must be withdrawn from the study if the following
occurs:
- At the participants own request
- If, in the investigator’s opinion, continuation of the study would be
harmful to the subject’s wellbeing
Table 2 Eligibility criteria of the NOSTONE study
Inclusion criteria
Individuals fulfilling all of the following inclusion criteria are eligible for
study participation:
- Informed Consent as documented by signature
- Age 18 years or older
- Recurrent kidney stone disease (≥ 2 stone events within the last 10 years
prior to randomization)
- Any past kidney stone containing 50% or more of calcium oxalate,
calcium phosphate or a mixture of both
Exclusion criteria
The presence of any one of the following exclusion criteria will lead to
exclusion of the individual:
- Pharmacologic prevention for stone recurrence less than 3 months prior
to randomization
- Patients with secondary causes of recurrent calcareous nephrolithiasis
including:
- Severe eating disorders (anorexia or bulimia)
- Chronic inflammatory bowel disease, bariatric surgery, intestinal
surgery with malabsorbtion or chronic diarrhea
- Sarcoidosis
- Primary hyperparathyroidism
- Complete distal tubular acidosis
- Active malignancy
- Patients with the following medications:
- Thiazide or loop diuretics
- Carbonic anhydrase inhibitors (including topiramate)
- Xanthine oxidase inhibitors (febuxostat or allopurinol)
- Alkali, including potassium citrate or sodium bicarbonate
- 1,25 -OH Vitamin D (calcitriol)
- Calcium supplementation
- Bisphosphonates
- Denusomab
- Teriparatide
- Glucocorticoids
- Obstructive uropathy, if not treated successfully
- Urinary tract infection, if not treated successfully
- Chronic kidney disease (defined as CKD -EPI eGFR < 30 mL/min per
1,73 m2 body surface area)
- Patients with a kidney transplant
- > 3 gout arthritis episodes within one year prior to randomisation or
gout arthritis requiring uric acid lowering therapy
- Cystinuria at screening
- Hypokalemia (blood potassium level < 3 mmol/L) at screening
- Hyponatremia (blood sodium level < 125 mmol/L) at screening
- Pregnant and lactating women
- Previous (within 3 months prior to randomization) or concomitant
participation in another interventional clinical trial
- Inability to understand and follow the protocol
- Known allergy to the study drug
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placebo group of 0.20 and 0.45 at 12 and 36months
after study start, respectively; (v) hazard ratios for the
12.5, 25 and 50mg HCTZ doses of 0.90, 0.65 and 0.50,
respectively; (vi) power was set to be at least 80% and
alpha was fixed at a two-sided level of 0.05; (vii) an un-
weighted log-rank test for linear trend with local
alternatives.
Statistical analysis
The statistical analysis of the trial will be done at CTU
Bern by a statistician first blinded to the group allocation.
Blinding will remain in place until the statistician codes
the primary analysis of the primary and secondary out-
comes and produces a dummy report of the primary ana-
lysis using a randomly generated group variable. The true
group variable becomes open after the completion of the
dummy report and gives place to the final report of all the
analysis as well as the quality control by the independent
statistician. Primary analyses will be done using the full
analysis set according to the intention-to-treat principle
where all randomized patients will be analyzed in the allo-
cated group regardless of any protocol violations or early
treatment discontinuations. In the secondary per-protocol
analysis, we will evaluate primary and secondary outcomes
based on the per-protocol analysis set (i.e. considering
only subjects who effectively followed the protocol). No
formal interim analysis is planned.
Primary analysis
We will assess the time to the stone event using the
log-rank test stratified for the number of stones at
baseline, Kaplan-Meier curves stratified by treatment
dose and hazard ratios between dosage groups using
the Cox proportional hazards. Comparisons between
placebo and the three active trial arms will be consid-
ered exploratory, as the trial is not powered to detect
differences with placebo. Components of the primary
outcome will be analyzed as the primary outcome.
Secondary outcomes (changes in urinary biochemistry
from baseline and through the study) will be analyzed
using the random effects model.
Secondary analysis
We will assess the impact of baseline disease severity on
stone recurrence; the impact of biochemical abnormal-
ities on stone recurrence; and the impact of stone com-
position on stone using the multivariable Cox-model .
Sensitivity analysis and some additional analyses
We will compare the full analysis set and per protocol
analysis of continuous outcomes based on multiple impu-
tations with the analysis of all available cases. We will as-
sess the sensitivity of time-to- stone-event approach
comparing it with multiple event models or frailty (count)
models or marginal count models. In the secondary ana-
lysis in case of a relevant number of patients with multiple
events, we will consider a shared-frailty Cox model for
multiple recurrent events.
Quality assurance and control
Monitoring
Sites are monitored centrally and by on-site visits by
trained monitors of CTU Bern following ICH-GCP guide-
lines. Trial sites are also regularly visited by the study co-
ordinator and the study sponsor to ensure compliance
with study protocol and ICH-GCP guidelines. Complete
source data verification (SDV) will be performed by inde-
pendent monitors.
Data management
All the data collected during the trial are stored in a se-
cure electronic data capture system (secuTrial®) accord-
ing to ICH-GCP guidelines. Secure backup is guaranteed
by the University of Bern.
Study organization
A steering committee oversaw the study design and over-
views the conduct of the study. The steering committee is
assisted by an advisory committee made up of three
experts of international renown in the field of clinical
studies or kidney stone disease. A central study coordin-
ator coordinates the study. CTU Bern monitors study
progress and quality and completeness of study data.
Conclusions
Kidney stones belong to the most frequent human diseases
and constitute a global health problem. Kidney stones are
extremely painful, relapse frequently and cause enormous
health care expenditures and excess morbidity. Thus, a
well-tolerated, inexpensive and effective approach to prevent
kidney stones is highly desired. While thiazides have been
the cornerstone of pharmacologic metaphylaxis for several
decades, evidence for benefits and harms of thiazides in gen-
eral and dose-response relationship in particular in the
recurrence prevention of kidney stones remain unclear.
Strengths of the NOSTONE study include the large
number of patients studied, the prospective multicenter,
parallel-arm, double-blind and placebo-controlled design
with stratification by disease activity, the clear allocation
concealment and intention-to-treat analysis, the employ-
ment of high sensitivity and high specificity imaging, the
use of state-of-the-art dietary recommendations, the
careful assessment of putative side effects in the stone
population and the exclusive public funding support.
The results of the NOSTONE trial will provide pa-
tients and physicians alike with long-sought evidence to
adapt and hopefully improve preventive measures for
calcium containing kidney stones.
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